303 related articles for article (PubMed ID: 1855478)
1. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen.
Abe-Hashimoto J; Kikuchi T; Matsumoto T; Nishii Y; Ogata E; Ikeda K
Cancer Res; 1993 Jun; 53(11):2534-7. PubMed ID: 8495416
[TBL] [Abstract][Full Text] [Related]
3. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
[TBL] [Abstract][Full Text] [Related]
4. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
5. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
[TBL] [Abstract][Full Text] [Related]
6. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
11. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
[TBL] [Abstract][Full Text] [Related]
12. A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice.
Abe J; Takita Y; Nakano T; Miyaura C; Suda T; Nishii Y
Endocrinology; 1989 May; 124(5):2645-7. PubMed ID: 2539984
[TBL] [Abstract][Full Text] [Related]
13. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
14. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
15. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death.
Wang Q; Yang W; Uytingco MS; Christakos S; Wieder R
Cancer Res; 2000 Apr; 60(7):2040-8. PubMed ID: 10766196
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels.
Pakkala S; de Vos S; Elstner E; Rude RK; Uskokovic M; Binderup L; Koeffler HP
Leuk Res; 1995 Jan; 19(1):65-72. PubMed ID: 7837819
[TBL] [Abstract][Full Text] [Related]
17. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth.
Okano K; Usa T; Ohtsuru A; Tsukazaki T; Miyazaki Y; Yonekura A; Namba H; Shindoh H; Yamashita S
Endocr J; 1999 Apr; 46(2):243-52. PubMed ID: 10460008
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice.
Matsumoto H; Iino Y; Koibuchi Y; Andoh T; Horii Y; Takei H; Horiguchi J; Maemura M; Yokoe T; Morishita Y
Oncol Rep; 1999; 6(2):349-52. PubMed ID: 10023003
[TBL] [Abstract][Full Text] [Related]
19. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion.
Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E
J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
